
Opinion|Videos|March 27, 2025
Monitoring Strategies for Managing ADC Toxicities in mBC
Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- Toxicity management is critical for patients on antibody-drug conjugates (ADCs). What are the most important ADC-related AEs that pharmacists should monitor (eg, neutropenia, diarrhea, ILD, mucositis) for T-DXd, SG, and Dato-DXd?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare's New GLP-1 Bridge Program: What Pharmacists Need to Know Before Dispensing
2
FDA Approves Ennumo, Pegfilgrastim Biosimilar Referencing Neulasta, for Febrile Neutropenia and Radiation Exposure
3
FDA Expands Wilate Approval for Routine Prophylaxis in Children Younger Than 6 With von Willebrand Disease
4
Single-Shot Respiratory Vaccine Could Transform Pharmacist Counseling and Immunization Rates
5











































































































